阿托伐他汀钙I和Ⅱ晶型的制备和表征

摘要

由阿托伐他汀内酯制备了阿托伐他汀钙I晶型，通过I晶型的悬浮转晶得到Ⅱ晶型；对I和Ⅱ晶型进行了固相表征，包括扫描电镜分析，X射线粉末衍射分析，卡尔费休水含量分析，热分析以及等温吸湿性分析；结果表明，I和Ⅱ晶型均为三水合物，但I晶型中3个水分子为2分子的通道水和1分子的结合水，Ⅱ晶型则为通道型水合物。

	Service

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	Email Alert
	RSS
	作者相关文章
	王悦伟
	张天巍
	柳泉
	张士欣
	龚俊波

关键词：阿托伐他汀钙水合物吸附脱附

Abstract：

In this paper, atorvastatin calcium form I was prepared from atorvastatin lactone. Form Ⅱ was obtained through the slurring experiment of form I. Forms I and Ⅱ were further characterized by scanning electron microscopy, powder X-ray diffractometry, KF water content analysis, thermal analysis and isothermal moisture absorption analysis. The results indicate that forms I and Ⅱ are both trihydrate; Form I contains two channel water and one isolated site water in its crystal lattice; Form Ⅱ is channel hydrate.

Keywords： atorvastatin calcium； hydrate； adsorption； desorption

Received 2014-04-29;

Fund:

国家自然科学基金（21176173）。

Corresponding Authors: 龚俊波,E-mail:Junbo_gong@tju.edu.cn。 Email: Junbo_gong@tju.edu.cn

About author: 王悦伟(1983-),男,助理工程师。

引用本文:

王悦伟, 张天巍, 柳泉, 张士欣, 龚俊波.阿托伐他汀钙I和Ⅱ晶型的制备和表征[J]. 化学工业与工程, 2016,33(4): 28-32

Wang Yuewei, Zhang Tianwei, Liu Quan, Zhang Shixin, Gong Junbo.Preparation and Characterization of Atorvastatin Calcium Form I & Ⅱ[J]. Chemcial Industry and Engineering, 2016,33(4): 28-32

[1] Bernstein J. Polymorphism-A perspective[J]. Crystal Growth Des, 2011, 11: 632-650
[2] Cabri W, Ghetti P, Alpegiani M,et al. Cefdinir: A comparative study of anhydrous vs. monohydrate form: Microstructure and tabletting behavior[J]. Eur J Pharm Biopharm, 2006, 64: 212-221
[3] Kawashima Y, Niwa T, Takeuchi H, et al. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques[J]. J Pharm Sci, 1991, 80: 472-478
[4] Allen P, Rahn P, Sarapu A, et al. Physical characterization of erythromycin: Anhydrate, monohydrate, and dihydrate crystalline solids[J]. J Pharm Sci, 1978, 67: 1 087-1 093
[5] Henwood S, Liebenberg W, Tiedt L, et al. Characterization of the solubility and dissolution properties of several new rifampicin polymorphs, solvates, and hydrates[J]. Drug Dev Ind Pharm, 2001, 27: 1 017-1 030
[6] Hilfiker R. Polymorphism in the pharmaceutical industry[M]. Weinheim: Hilfiker R, 2006
[7] Tian F, Qu H, Zimmermann A, et al. Factors affecting crystallization of hydrates[J]. J Pharm Pharmacol, 2010, 62: 1 534-1 546
[8] Zimmermann A, Tian F, Diego H, et al. Structural characterization and dehydration behavior of siramesine hydrochloride[J]. J Pharm Sci, 2009, 98: 3 596-3 607
[9] Sun C, Zhou D, Grant D,et al. Theophylline monohydrate[J]. Acta Crystallorg Sect E, 2002, 58: 368-370
[10] Gossman W, Wilson S, Oldfield E. Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures[J]. Acta Crystallogr C, 2003, 59: 33-36
[11] Briggs C, Harasawa K, Ichikawa S, et al. Crystalline[R-(R*,R*)]-2-(4-dfluorophenyl)-β,α-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-lH-pyrrole-1-heptanoic acid hemi calcium salt (Atorvastatin): US, 005969156[P]. 1999-10-19
[12] Giron D, Goldbronn C, Mutz M, et al. Solid state characterizations of pharmaceutical hydrates[J]. J Therm Anal Calorim, 2002, 68: 453-465
[13] 王博超. 盐酸多奈哌齐结晶过程研究[D]. 天津: 天津大学, 2008